# iRhythm Holdings, Inc. (IRTC)

Informational only - not investment advice.

CIK: 0001388658
SIC: 3841 Surgical & Medical Instruments & Apparatus
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3841 Surgical & Medical Instruments & Apparatus](/industry/3841/)
Latest 10-K filed: 2026-02-19
SEC page: https://www.sec.gov/edgar/browse/?CIK=1388658
Filing source: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000011/irtc-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-19 · accession 0001388658-26-000011 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001388658.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 747,138,000 USD | 2025 | verified |
| Net income | -44,551,000 USD | 2025 | verified |
| Assets | 1,020,042,000 USD | 2025 | verified |
| Free cash flow | 34,521,000 USD | 2025 | computed |
| Net margin | -5.96% | 2025 | computed |
| Operating margin | -7.68% | 2025 | computed |
| Revenue YoY | +26.24% | 2025 | computed |
| ROE | -29.17% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | IRTC | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -6.0% | -6.0% | 50 | 63 |
| Operating margin | -7.7% | -2.7% | 44 | 63 |
| Revenue growth | 26.2% | 13.6% | 81 | 64 |
| FCF margin | 4.6% | 0.2% | 63 | 63 |
| ROE | -29.2% | -9.1% | 25 | 58 |
| ROA | -4.4% | -4.8% | 52 | 65 |
| Liabilities / equity | 5.68 | 0.89 | 90 | 63 |
| Current ratio | 4.63 | 3.23 | 66 | 65 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3841 Surgical & Medical Instruments & Apparatus, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 747138000 | USD | 2025 | 2026-02-19 |
| Net income | -44551000 | USD | 2025 | 2026-02-19 |
| Assets | 1020042000 | USD | 2025 | 2026-02-19 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-19. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001388658.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 64,072,000 | 99,129,000 | 147,277,000 | 214,552,000 | 265,166,000 | 322,825,000 | 410,921,000 | 492,681,000 | 591,839,000 | 747,138,000 |
| Net income | -20,903,000 | -29,740,000 | -50,378,000 | -54,568,000 | -43,830,000 | -101,361,000 | -116,155,000 | -123,406,000 | -113,289,000 | -44,551,000 |
| Operating income | -15,582,000 | -27,591,000 | -45,691,000 | -54,755,000 | -43,673,000 | -99,943,000 | -113,784,000 | -125,161,000 | -115,505,000 | -57,407,000 |
| Gross profit | 43,189,000 | 70,926,000 | 108,482,000 | 162,067,000 | 194,889,000 | 213,567,000 | 281,632,000 | 331,806,000 | 407,531,000 | 527,250,000 |
| Diluted EPS |  |  |  | -2.16 | -1.58 | -3.46 | -3.88 | -4.04 | -3.63 | -1.39 |
| Operating cash flow | -16,651,000 | -14,911,000 | -29,093,000 | -21,863,000 | -13,759,000 | -37,753,000 | -23,012,000 | -50,101,000 | 3,390,000 | 80,863,000 |
| Capital expenditures | 2,763,000 | 3,562,000 | 5,180,000 | 20,457,000 | 13,551,000 | 28,067,000 | 29,830,000 | 40,424,000 | 33,942,000 | 46,342,000 |
| Share buybacks |  |  |  |  |  |  | 0.00 | 0.00 | 25,000,000 | 0.00 |
| Assets | 138,156,000 | 133,123,000 | 117,523,000 | 306,212,000 | 511,739,000 | 462,967,000 | 448,222,000 | 433,144,000 | 931,449,000 | 1,020,042,000 |
| Liabilities | 45,594,000 | 53,570,000 | 65,386,000 | 170,803,000 | 170,127,000 | 183,452,000 | 208,410,000 | 223,047,000 | 840,541,000 | 867,296,000 |
| Stockholders' equity | 93,041,000 | 79,341,000 | 52,137,000 | 135,409,000 | 341,612,000 | 279,515,000 | 239,812,000 | 210,097,000 | 90,908,000 | 152,746,000 |
| Cash and cash equivalents | 51,643,000 | 8,671,000 | 20,023,000 | 20,462,000 | 88,628,000 | 127,562,000 | 78,832,000 | 36,173,000 | 419,597,000 | 236,012,000 |
| Free cash flow | -19,414,000 | -18,473,000 | -34,273,000 | -42,320,000 | -27,310,000 | -65,820,000 | -52,842,000 | -90,525,000 | -30,552,000 | 34,521,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | -32.62% | -30.00% | -34.21% | -25.43% | -16.53% | -31.40% | -28.27% | -25.05% | -19.14% | -5.96% |
| Operating margin | -24.32% | -27.83% | -31.02% | -25.52% | -16.47% | -30.96% | -27.69% | -25.40% | -19.52% | -7.68% |
| Return on equity | -22.47% | -37.48% | -96.63% | -40.30% | -12.83% | -36.26% | -48.44% | -58.74% | -124.62% | -29.17% |
| Return on assets | -15.13% | -22.34% | -42.87% | -17.82% | -8.56% | -21.89% | -25.91% | -28.49% | -12.16% | -4.37% |
| Liabilities / equity | 0.49 | 0.68 | 1.25 | 1.26 | 0.50 | 0.66 | 0.87 | 1.06 | 9.25 | 5.68 |
| Current ratio | 8.98 | 5.72 | 3.44 | 3.32 | 5.75 | 3.48 | 3.24 | 2.15 | 5.82 | 4.63 |

## As-reported value updates

4 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/IRTC/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001388658.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.71 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -1.29 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.61 | reported discrete quarter |
| 2023-Q3 | 2023-06-30 |  | -18,482,000 |  | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 124,604,000 |  | -0.89 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 132,511,000 | -38,699,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 131,929,000 | -45,667,000 | -1.47 | reported discrete quarter |
| 2024-Q2 | 2024-03-31 |  | -45,667,000 |  | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 148,047,000 |  | -0.65 | reported discrete quarter |
| 2024-Q3 | 2024-06-30 |  | -20,107,000 |  | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 147,538,000 |  | -1.48 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 164,325,000 | -1,333,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 158,677,000 | -30,700,000 | -0.97 | reported discrete quarter |
| 2025-Q2 | 2025-03-31 |  | -30,700,000 |  | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 186,687,000 |  | -0.44 | reported discrete quarter |
| 2025-Q3 | 2025-06-30 |  | -14,218,000 |  | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 192,884,000 |  | -0.16 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 208,890,000 | 5,579,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 199,390,000 | -13,933,000 | -0.43 | reported discrete quarter |
| 2026-Q2 | 2026-03-31 |  | -13,933,000 |  | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 224,172,000 |  | -0.01 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from IRTC's latest 10-K: [/company/IRTC/business/](/company/IRTC/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from IRTC's latest 10-K: [/company/IRTC/risk-factors/](/company/IRTC/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000072/irtc-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-06
Report date: 2026-06-30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Quarterly Report on Form 10-Q entitled “Risk Factors.”

Overview

We are a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.

Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias.

Since first receiving clearance from FDA for our technology in 2009, we have supported physician and patient use of this technology and provided ACM services from our Medicare-enrolled IDTFs and with our qualified technicians. We have provided our iRhythm Services using our iRhythm ACM System. Since receiving FDA clearance, we have provided the iRhythm Services via more than 13 million patient reports and have collected over 3 billion hours of curated heartbeat data.

We receive revenue for our iRhythm Services primarily from third-party payors, which include contracted third-party payors and CMS. The remainder of our revenue comes from healthcare institutions, which are typically hospitals or private physician practices, who purchase the iRhythm Services from us directly. We rely on third-party billing partners to submit patient claims and collect from commercial payors, certain government agencies, and patients.

The following are iRhythm Services shown as a percentage of revenue:

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Six Months Ended June 30,"],["","2026","","2025","","2026","","2025"],["Contracted third-party payors","51%","","52%","","52%","","52%"],["Centers for Medicare & Medicaid Services","26%","","24%","","26%","","24%"],["Healthcare institutions","17%","","17%","","16%","","17%"],["Non-contracted third-party payors","6%","","7%","","6%","","7%"]]
[[/GREPCENT_TABLE]]

Cybersecurity Incident

In June 2026, a threat actor improperly obtained certain sensitive information of ours maintained on certain third-party-hosted business applications (the “Cybersecurity Incident”). We promptly activated our cybersecurity response plan and launched an investigation with the support of external advisors and cybersecurity experts to assess and contain the threat, and, as of the date of the filing of this Quarterly Report on Form 10-Q, we have not identified evidence of ongoing unauthorized access to our systems.

28

During the second quarter of 2026, we incurred losses related to the unauthorized activity, including investigation and remediation costs. We maintain cybersecurity insurance coverage to limit our exposure to losses such as those related to the Cybersecurity Incident. While we expect to incur further expenses related to the Cybersecurity Incident, inclusive of customer and patient notifications and identity protection, we plan to seek reimbursement of some of these losses by submitting claims to our insurers. There can be no assurance that such coverage will be sufficient to cover all losses we may incur, and the exact timing and amount of any such reimbursements is not known at this time. As of the date of the filing of this Quarterly Report on Form 10-Q, we believe that the Cybersecurity Incident is not reasonably likely to have a material impact on our financial condition or results of operations. For more information about risks relating to the impact of the Cybersecurity Incident, see Item 1A. “Risk Factors” in Part II of this Quarterly Report on Form 10-Q.

We have also been named as a defendant in several lawsuits related to the Cybersecurity Incident (Refer to Note 7, Commitments and Contingencies, in the notes to our unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q).

Key Business Metric

Non-GAAP Financial Measure

Adjusted EBITDA is a key measure we use to assess our financial performance and it is also used for internal planning and forecasting purposes. We believe Adjusted EBITDA is helpful to investors, analysts, and other interested parties because it can assist in providing a more consistent and comparable overview of our operational performance across our historical financial periods. In addition, this measure is frequently used by analysts, investors, and other interested parties to evaluate and assess performance.

We define Adjusted EBITDA for a particular period as net income (loss) before income tax provision, depreciation and amortization, interest expense, and interest income and as further adjusted for stock-based compensation expense, changes in fair value of strategic investments, impairment charges, business transformation costs, certain intellectual property litigation expenses, certain corporate litigation settlements (net of expected insurance recoveries), costs related to the Cybersecurity Incident (net of expected insurance recoveries), and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only and should not be considered as an alternative or substitute to financial information presented in accordance with GAAP. This measure has certain limitations in that it does not include the impact of certain expenses that are reflected in our unaudited condensed consolidated statements of operations that are necessary to run our business. We may identify additional charges and gains to exclude from Adjusted EBITDA that are significant in nature which may impact period to period comparability and do not represent the ongoing results of the business. Other companies, including other companies in our industry, may not use this measure or may calculate this measure differently than as presented in this Quarterly Report on Form 10-Q, limiting its usefulness as a comparative measure.

The following table presents a reconciliation of Net loss, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EBITDA (in thousands):

29

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Six Months Ended June 30,"],["","2026","","2025","","2026","","2025"],["Net loss1","$","(381)","","","$","(14,218)","","","$","(14,314)","","","$","(44,918)"],["Interest expense","3,294","","","3,278","","","6,584","","","6,551"],["Interest income","(4,776)","","","(5,321)","","","(9,655)","","","(10,240)"],["Changes in fair value of strategic investments","(822)","","","(2,152)","","","(2,269)","","","(2,995)"],["Income tax provision (benefit)","\u2014","","","(183)","","","500","","","482"],["Depreciation and amortization","5,222","","","5,105","","","10,264","","","10,315"],["Stock-based compensation","20,039","","","22,827","","","41,530","","","46,171"],["Impairment charges","\u2014","","","2,479","","","\u2014","","","2,479"],["Business transformation costs","1,158","","","925","","","1,504","","","1,428"],["Intellectual property litigation expenses","4,928","","","2,956","","","8,617","","","3,788"],["Litigation settlements","13,950","","","\u2014","","","13,950","","","\u2014"],["Cybersecurity incident","686","","","\u2014","","","686","","","\u2014"],["Adjusted EBITDA","$","43,298","","","$","15,696","","","$","57,397","","","$","13,061"]]
[[/GREPCENT_TABLE]]

1 Net loss for the three and six months ended June 30, 2026 includes $0.3 million and $0.6 million of acquired in-process research and development expense, and $1.7 million and $2.0 million for the three and six months ended June 30, 2025, respectively.

Macroeconomic Factors

Our future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments of outstanding receivables, supply chain disruptions or shortages, commodity price increases, tariffs on imports, and inflationary pressure, uncertain or reduced demand, a tightening labor market, and the impact of any initiatives or programs that we may undertake to address financial and operational challenges faced by our customers.

The current macroeconomic environment is impacting our customers, both financially and operationally. Hospitals are experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, interest rate volatility make access to credit more expensive, and unrealized losses decrease available cash reserves. As a consequence of the financial pressures and decreased profitability, some hospitals have indicated that they are lowering their capital investment plans and tightening their operational budgets. Private and government payors around the world are increasingly challenging the utilization and overall cost charged for medical products and services. The containment of healthcare costs has become a priority of governments on a global basis. Private and government payors may decline to cover and reimburse for claims or portions of claims. Climate-related events, including the increasing frequency of extreme weather events, natural disasters, or other catastrophic events may cause damage or disruption to our domestic or global customers or our operations, which could have an adverse effect on our business, operating results, and financial condition.

We have adapted our iRhythm Services to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of our home enrollment service, which allows patients to receive and wear the single-use Zio patch without going to a healthcare facility.

Our hybrid work arrangements and decision to pursue a sublease have previously resulted in an impairment of our right-of-use asset and related leasehold improvements and furniture and fixtures. As we continue to evaluate our global real estate footprint, we may incur additional impairment charges related to real property lease agreements.

30

Revenue, net

The majority of our revenue is derived from provision of our iRhythm Services to customers in the United States. We earn revenue from the provision of our iRhythm Services primarily from contracted third-party payors, CMS, and healthcare institutions. A small percentage of our revenue is from non-contracted third-party payors.

We recognize revenue on an accrual basis based on estimates of the amount that will ultimately be realized, which considers the amount submitted for payment and the

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000011/irtc-20251231.htm
Complete FY 2025 MD&A: /company/IRTC/mda/fy2025/

Extracted from a substantive MD&A body after the formal Item 7 span was a TOC or reference stub.
Confidence: high
Filing date: 2026-02-19
Report date: 2025-12-31

Overview

We are a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.

Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias.

Since first receiving clearance from FDA for our technology in 2009, we have supported physician and patient use of this technology and provided ACM services from our Medicare-enrolled IDTFs and with our qualified technicians. We have provided our iRhythm Services using our iRhythm ACM Systems. Since receiving FDA clearance, we have provided the iRhythm Services via more than twelve million patient reports and have collected almost 3 billion hours of curated heartbeat data.

We receive revenue for our iRhythm Services primarily from third-party payors, which include contracted third-party payors and CMS. The remainder of our revenue comes from healthcare institutions, which are typically hospitals or private physician practices, who purchase the iRhythm Services from us directly. We rely on third-party billing partners to submit patient claims and collect from commercial payors, certain government agencies, and patients.

The following are iRhythm Services shown as a percentage of revenue:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","2024","","2023"],["Contracted third-party payors","","52","%","","53","%","","54","%"],["Centers for Medicare and Medicaid","","24","%","","24","%","","25","%"],["Healthcare institutions","","17","%","","16","%","","14","%"],["Non-contracted third party payors","","7","%","","7","%","","7","%"]]
[[/GREPCENT_TABLE]]

66

Key Business Metric

Non-GAAP Financial Measure

Adjusted EBITDA is a key measure we use to assess our financial performance and it is also used for internal planning and forecasting purposes. We believe Adjusted EBITDA is helpful to investors, analysts, and other interested parties because it can assist in providing a more consistent and comparable overview of our operational performance across our historical financial periods. In addition, this measure is frequently used by analysts, investors, and other interested parties to evaluate and assess performance.

We define Adjusted EBITDA for a particular period as net loss before income tax provision, depreciation and amortization, interest expense, and interest income and as further adjusted for stock-based compensation expense, changes in fair value of strategic investments, impairment charges, business transformation costs, certain intellectual property litigation expenses and settlements, and loss on extinguishment of debt. Beginning in the first quarter of 2025, certain intellectual property litigation expenses that we have excluded from Adjusted EBITDA include third-party attorneys' fees and expenses associated with patent litigation brought against iRhythm Technologies by Welch Allyn and BardyDx. Factors we considered in arriving at this determination to exclude these patent litigation costs from our Adjusted EBITDA include frequency and complexity of the patent litigation, the counterparty involved, and the expected magnitude of patent litigation costs for this matter. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only and should not be considered as an alternative or substitute to financial information presented in accordance with GAAP. This measure has certain limitations in that it does not include the impact of certain expenses that are reflected in our consolidated statements of operations that are necessary to run our business. We may identify additional charges and gains to exclude from Adjusted EBITDA that are significant in nature which may impact period to period comparability and do not represent the ongoing results of the business. Other companies, including other companies in our industry, may not use this measure or may calculate this measure differently than as presented in this Annual Report on Form 10-K, limiting its usefulness as a comparative measure.

The following table presents a reconciliation of Net loss, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EBITDA (in thousands):

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","2024","","2023"],["Net loss1","","$","(44,551)","","","$","(113,289)","","","$","(123,406)"],["Interest expense","","13,154","","","12,821","","","3,650"],["Interest income","","(21,521)","","","(21,938)","","","(6,353)"],["Changes in fair value of strategic investments","","(5,711)","","","(1,902)","","","\u2014"],["Income tax provision","","953","","","565","","","750"],["Depreciation and amortization","","20,742","","","20,715","","","16,348"],["Stock-based compensation","","88,283","","","75,978","","","77,204"],["Impairment charges","","4,458","","","641","","","11,078"],["Business transformation costs","","3,033","","","11,072","","","15,866"],["Intellectual property litigation expenses2","","10,070","","","\u2014","","","\u2014"],["Loss on extinguishment of debt","","\u2014","","","7,589","","","\u2014"],["Adjusted EBITDA","","$","68,910","","","$","(7,748)","","","$","(4,863)"]]
[[/GREPCENT_TABLE]]

1 Net loss for the year ended December 31, 2025 and 2024 includes $3.0 million and $32.4 million of acquired in-process research and development expense, respectively.

2 Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.

67

Macroeconomic Factors

Our future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments of outstanding receivables, supply chain disruptions, including shortages, tariffs on imports, and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that we may undertake to address financial and operational challenges faced by our customers.

The current macroeconomic environment is impacting our customers, both financially and operationally. Hospitals are experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, interest rate volatility make access to credit more expensive, and unrealized losses decrease available cash reserves. As a consequence of the financial pressures and decreased profitability, some hospitals have indicated that they are lowering their capital investment plans and tightening their operational budgets. Private and government payors around the world are increasingly challenging the utilization and overall cost charged for medical products and services. The containment of healthcare costs has become a priority of governments on a global basis. Private and government payors may decline to cover and reimburse for claims or portions of claims. Climate-related events, including the increasing frequency of extreme weather events, natural disasters, or other catastrophic events may cause damage or disruption to our domestic or global customers or our operations, which could have an adverse effect on our business, operating results, and financial condition.

We have adapted our iRhythm Services to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of our home enrollment service, which allows patients to receive and wear the single-use Zio patch without going to a healthcare facility.

Our hybrid work arrangements and decision to pursue a sublease have previously resulted in an impairment of our right-of-use asset and related leasehold improvements and furniture and fixtures. As we continue to evaluate our global real estate footprint, we may incur additional impairment charges related to real property lease agreements.

Revenue, net

The majority of our revenue is derived from provision of our iRhythm Services to customers in the United States. We earn revenue from the provision of our iRhythm Services primarily from contracted third-party payors, CMS, and healthcare institutions. A small percentage of our revenue is from non-contracted third-party payors.

We recognize revenue on an accrual basis based on estimates of the amount that will ultimately be realized, which considers the amount submitted for payment and the amount received. These estimates require significant judgment by management. In determining the amount to accrue for the iRhythm Services (including a delivered report), we consider factors such as claim payment history from both payors and patient, available reimbursement, including whether there is a contract between us and the payor or healthcare institution and historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments.

We have historically experienced reduced revenue during the third quarter, as well as during the year-end holiday season. We believe this is the result of physicians and patients taking vacations and patients electing to delay our monitoring services during the summer months or holidays. Revenue may be impacted by the outcome of adjudications with contracted and non-contracted payors, as well as changes in CMS reimbursement rates that are updated annually.

Cost of Revenue

Cost of revenue includes direct labor, material costs, tariffs, equipment and infrastructure expenses, amortization of internal-use software, allocated overhead, royalties, and shipping and handling. Direct labor includes payroll-related costs including stock-based compensation involved in manufacturing, clinical data curation, and customer service. Material costs include both the disposable materials costs of the Zio patches and amortization of the PCBAs. Each Zio XT and Zio monitor includes a PCBA, and each Zio AT includes a PCBA and gateway board, the cost of which is amortized over the expected useful life of the board. We expect cost of revenue to increase in absolute dollars as our revenue increases due to increased direct labor, direct materials, and variable spending, as well as amortization of internal-use software, partially offset by economies of scale in relation to fixed costs such as overhead and facilities costs.

68

Our gross margin has been and will continue to be affected by a variety of factors, including increased contracting with third-party payors and institutional providers. We have in the past been able to increase our pricing as third-party payors become more familiar with the benefits of the iRhythm Services and move to contracted pricing arrangements. We expect increases to the cost of revenues due to increases to materials and electronics components pricing, labor rates, shipping rates, amortization of capitalized internal-use software, along with increases in the general level of inflation and tariffs on imports (which may complicate and increas

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/IRTC/mda/fy2025/
All MD&A years: /company/IRTC/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/IRTC/mda/fy2024/): filed 2025-02-20; accession 0001388658-25-000028 (https://www.sec.gov/Archives/edgar/data/1388658/000138865825000028/irtc-20241231.htm)
- [FY 2023 MD&A](/company/IRTC/mda/fy2023/): filed 2024-02-22; accession 0001388658-24-000014 (https://www.sec.gov/Archives/edgar/data/1388658/000138865824000014/irtc-20231231.htm)
- [FY 2022 MD&A](/company/IRTC/mda/fy2022/): filed 2023-02-23; accession 0001388658-23-000007 (https://www.sec.gov/Archives/edgar/data/1388658/000138865823000007/irtc-20221231.htm)
- [FY 2021 MD&A](/company/IRTC/mda/fy2021/): filed 2022-02-28; accession 0001388658-22-000020 (https://www.sec.gov/Archives/edgar/data/1388658/000138865822000020/irtc-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 3841 Surgical & Medical Instruments & Apparatus) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/IRTC.md · JSON record: /company/IRTC.json · verified financials: /company/IRTC/financials.json / /company/IRTC/financials.csv · machine TOC for the whole site: /llms.txt